Efficacy of dupilumab for airway hypersecretion and airway wall thickening in patients with moderate-to-severe asthma: A prospective, observational study
Allergology International · 2024
DOI: 10.1016/j.alit.2024.02.002 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Allergology International, 2024. Verfasst von Tomoko Tajiri und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Allergy and Clinical Immunology, Graduate School of Medical Sciences, Nagoya City University, Aichi, Japan. Elect…. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized, Severity of Illness Index. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Dupilumab has clinical effects in patients with moderate-to-severe asthma. When considering interleukin (IL)-4 and IL-13 signaling, effects of dupilumab on airway mucus hypersecretion and airway remodeling are expected, but they have been reported in only a few short-term studies. Its efficacy for airway hyperresponsiveness (AHR) remains unknown. We comprehensively assessed the efficacy of dupilumab, especially for subjective and objective measures of airway mucus hypersecretion and airway dimensions in moderate-to-severe asthmatic patients. METHODS: In 28 adult patients with moderate-to-severe uncontrolled asthma, the comprehensive efficacy of 48-week dupilumab treatment, including the Cough and Sputum Assessment Questionnaire (CASA-Q), radiological mucus scores and airway dimensions on computed tomography (CT), was assessed prospectively. Treatment responsiveness to dupilumab was analyzed. RESULTS: With 48-week dupilumab treatment, all four cough and sputum domain scores of CASA-Q improved significantly. Radiological mucus scores and airway wall thickening on CT were significantly decreased. The decreases in mucus scores were significantly associated with improvements in Asthma Control Questionnaire scores, Asthma Quality of Life Questionnaire (AQLQ) overall scores, airway obstruction, and airway type 2 inflammation. When defined by > 0.5 improvement in AQLQ overall scores, 18 patients (64%) were identified as responders. CONCLUSIONS: Dupilumab reversed subjective and objective measures of airway mucus hypersecretion and some aspects of airway remodeling in patients with moderate-to-severe uncontrolled asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Allergy and Clinical Immunology, Graduate School of Medical Sciences, Nagoya City University, Aichi, Japan. Electronic address: tomokot@med.nagoya-cu.ac.jp.
- Department of Otorhinolaryngology, Graduate School of Medical Sciences, Nagoya City University, Aichi, Japan; Department of Otorhinolaryngology, Nagoya City University Midori Municipal Hospital, Aichi, Japan.
- Department of Respiratory Medicine, Allergy and Clinical Immunology, Graduate School of Medical Sciences, Nagoya City University, Aichi, Japan.
- Department of Radiology, School of Medicine, Fujita Health University, Aichi, Japan.
- Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan.
Zitieren
APA
Tajiri, T., Suzuki, M., Nishiyama, H., Ozawa, Y., Kurokawa, R., Takeda, N., Ito, K., Fukumitsu, K., Kanemitsu, Y., Mori, Y., Fukuda, S., Uemura, T., Ohkubo, H., Takemura, M., Maeno, K., Ito, Y., Oguri, T., Izuhara, K., & Niimi, A. (2024). Efficacy of dupilumab for airway hypersecretion and airway wall thickening in patients with moderate-to-severe asthma: A prospective, observational study. Allergology International. https://doi.org/10.1016/j.alit.2024.02.002
Vancouver
Tajiri T, Suzuki M, Nishiyama H, Ozawa Y, Kurokawa R, Takeda N, et al. Efficacy of dupilumab for airway hypersecretion and airway wall thickening in patients with moderate-to-severe asthma: A prospective, observational study. Allergology International. 2024. doi:10.1016/j.alit.2024.02.002
BibTeX
@article{Tajiri2024,
author = {Tajiri, Tomoko and Suzuki, Motohiko and Nishiyama, Hirono and Ozawa, Yoshiyuki and Kurokawa, Ryota and Takeda, Norihisa and Ito, Keima and Fukumitsu, Kensuke and Kanemitsu, Yoshihiro and Mori, Yuta and Fukuda, Satoshi and Uemura, Takehiro and Ohkubo, Hirotsugu and Takemura, Masaya and Maeno, Ken and Ito, Yutaka and Oguri, Tetsuya and Izuhara, Kenji and Niimi, Akio},
title = {Efficacy of dupilumab for airway hypersecretion and airway wall thickening in patients with moderate-to-severe asthma: A prospective, observational study},
journal = {Allergology International},
year = {2024},
doi = {10.1016/j.alit.2024.02.002}
}
EUVIMED